Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Terminated 3Completed 2Suspended 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2CNS 1

Conditions

Neoplasms 2Neoplasm Metastasis 1Brain Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Terminated × taxane × Clear all
NCT02187822 2021-02-04

Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Terminated
15 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

NCT00326131 2010-03-02

A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer

Bristol-Myers Squibb

Phase 1 Terminated
6 enrolled
Tumor-Agnostic

Neoplasms

NCT00332748 2010-03-02

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

Bristol-Myers Squibb

Phase 1 Terminated
36 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡